What is Premenstrual Dysphoric Disorder (PMDD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Premenstrual Dysphoric Disorder (PMDD)

Premenstrual Dysphoric Disorder (PMDD) is a severe form of premenstrual syndrome characterized by intense mood symptoms, somatic symptoms, and cognitive symptoms that begin several days before menstruation, improve within days after onset, and become minimal or absent within one week following the onset of menses.

Definition and Classification

PMDD is officially recognized as a distinct psychiatric condition in modern diagnostic classifications:

  • Formally established as a depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) in 2013 1
  • Included in the International Classification of Diseases 11th Revision (ICD-11) as a distinct diagnostic entity 2

Epidemiology

  • PMDD affects approximately 3-8% of women of reproductive age 3
  • In contrast, milder premenstrual syndrome (PMS) affects 20-40% of menstruating women 1

Clinical Presentation

PMDD is characterized by a specific pattern of symptoms:

  • Timing pattern: Symptoms begin several days before menstruation, start improving within days after onset, and become minimal or absent within one week following menses 2

  • Core symptom categories:

    • Mood symptoms (e.g., depressed mood, irritability)
    • Somatic symptoms (e.g., bloating, breast tenderness, overeating)
    • Cognitive symptoms (e.g., forgetfulness, difficulty concentrating) 2
  • Severity: Symptoms are severe enough to significantly impact daily functioning, relationships, and quality of life 1

Pathophysiology

While the exact cause remains unclear, several mechanisms have been proposed:

  • Heightened sensitivity to normal hormonal fluctuations during the luteal phase 1, 3
  • Abnormal serotonergic activity 1
  • Aberrations in progesterone and gamma-aminobutyric acid (GABA) neurotransmission 1
  • Possible genetic predisposition affecting sensitivity to hormonal changes 4

Diagnosis

The diagnosis of PMDD requires:

  • Prospective symptom tracking using daily symptom ratings (e.g., Daily Record of Severity of Problems) 3
  • Documentation of symptoms occurring specifically during the luteal phase with resolution after menstruation begins
  • Confirmation that symptoms significantly impair functioning 1
  • Exclusion of other psychiatric disorders that may be exacerbated premenstrually

Treatment Options

First-line treatments:

  • Selective Serotonin Reuptake Inhibitors (SSRIs):

    • Most effective for both physical and mood symptoms 3
    • Can be administered continuously or only during the luteal phase
    • Continuous administration is more effective than luteal phase dosing (SMD -0.69 vs -0.39) 5
    • Common side effects include nausea, insomnia, sexual dysfunction, and fatigue 5
  • Combined Oral Contraceptives (OCPs):

    • Primarily improve physical symptoms 3
    • Work by suppressing ovulation and stabilizing hormone levels

Additional treatment options:

  • Non-pharmacologic approaches:

    • Lifestyle modifications (diet, exercise)
    • Cognitive behavioral therapy
    • Vitamin and herbal supplements (e.g., chasteberry)
    • Acupuncture 1
  • Other pharmacologic options:

    • GnRH agonists (for severe cases)
    • Non-contraceptive estrogen formulations 1

Differential Diagnosis

PMDD should be distinguished from:

  • Premenstrual exacerbation of underlying psychiatric disorders
  • Premenstrual syndrome (PMS) - milder form with less impact on functioning
  • Major depressive disorder
  • Anxiety disorders

Despite some symptomatic overlap with depression and anxiety disorders, PMDD is considered a distinct diagnostic entity with irritability and affect lability as its most characteristic features, rather than depressed mood or anxiety 6.

Clinical Pearls

  • PMDD symptoms are cyclical and specifically tied to the menstrual cycle, unlike other mood disorders
  • Prospective symptom tracking is essential for accurate diagnosis
  • SSRIs show a more rapid onset of action in PMDD than in depression or anxiety disorders 6
  • Cultural factors may influence the prevalence, expression, and reporting of symptoms 2
  • Women with a history of mood disorders may be at higher risk for developing PMDD 4

References

Research

Premenstrual syndrome and premenstrual dysphoric disorder in adolescents.

Current problems in pediatric and adolescent health care, 2022

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Prolactin and Breastfeeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.